择期pci对比急诊pci比伐卢定有效性及安全性的meta分析

《择期pci对比急诊pci比伐卢定有效性及安全性的meta分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20153135专业代码R541.4HebeiMedicalUniversity硕士学位论文专业学位择期PCI对比急诊PCI比伐卢定有效性及安全性的meta分析研究生：刘玉龙导师：王梅教授专业：内科学二级学院：河北医科大学第二医院2018年3月目录中文摘要·····································································································10英文摘要·······································

2、·······························································20研究论文择期PCI对比急诊PCI比伐卢定有效性及安全性的meta分析前言·····································································································40资料与方法··················································································

3、·····50结果··········································································································6附图··········································································································09附表·······························································

4、···········································23讨论··········································································································25结论··········································································································28参考文献······················

5、············································································28综述经皮冠脉介入治疗术中应用比伐卢定的研究进展····························33致谢··················································································································38个人简历······································

6、····································································39中文摘要择期PCI对比急诊PCI比伐卢定有效性及安全性的meta分析摘要目的：系统评价急性冠脉综合征患者行择期PCI对比急诊PCI比伐卢定的有效性及安全性。背景：目前，对于行PCI术的急性冠脉综合征患者，术中最佳抗凝策略仍然存在争议，更为重要的是，对比急诊PCI，择期PCI时应用比伐卢定的有效性及安全性研究鲜有报道。方法：文献检索主要在PubMed,EMBASE,CochraneLibrary,ClinicalTrials数据库中，采用R

7、evMan5.3软件进行数据统计学处理，根据患者是否常规应用GPIIb/Ⅲa拮抗剂（GPI）进行亚组分析。结果：最终，我们共纳入13项随机对照研究，共包括23500名患者。在急诊PCI患者中，比伐卢定显著降低患者30d内全因死亡(RR0.80;295%CI0.67to0.96;P=0.02;I=0%)、心源性死亡(RR0.76;95%CI0.59to20.98;P=0.04;I=0%)以及30d内严重出血风险(RR0.61;95%CI0.44to20.83;P=0.002,I=70%)，但是却增加患者心